[1]周 用,左 盼,吴哲骁,等.扶正消瘤方治疗肝动脉化疗栓塞术加经皮肝肿瘤射频消融术后肝癌临床研究*[J].陕西中医,2020,(11):1534-1538.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.005]
　ZHOU Yong,ZUO Pan,WU Zhexiao,et al.Effect of Fuzheng Xiaoliu prescription on patients with liver cancer after TACE plus RFA operation[J].,2020,(11):1534-1538.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.005]
点击复制

扶正消瘤方治疗肝动脉化疗栓塞术加经皮肝肿瘤射频消融术后肝癌临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年11期
页码:
1534-1538
栏目:
临床研究
出版日期:
2020-11-05

文章信息/Info

Title:
Effect of Fuzheng Xiaoliu prescription on patients with liver cancer after TACE plus RFA operation
作者:
周 用1; 左 盼1; 吴哲骁2; 刘嘉敏2; 曾 鹏1; 罗保平1△
1.湖北省中医院肿瘤科(武汉430070); 2.湖北中医药大学黄家湖医院(武汉430070)
Author(s):
ZHOU Yong; ZUO Pan; WU Zhexiao; et al.
Oncology Department,Hubei Hospital of Traditional Chinese Medicine(Wuhan 430070)
关键词:
扶正消瘤方;  肝癌;  正虚瘀结证;  谷氨酰转肽酶;  总胆红素
Keywords:
Fuzheng Xiaoliu granules;  Liver cancer;  Syndrome of positive deficiency and stasis;  GGT;  TBil
分类号:
R735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2020.11.005
文献标志码:
A
摘要:
目的:观察扶正消瘤方治疗Ⅰ期乙肝相关肝癌肝动脉化疗栓塞术(TACE)加经皮肝肿瘤射频消融术(RFA)术后患者的疗效。方法:选取病例312例,患者按照随机数字表法分为对照组和观察组各156例。对照组患者给予扶正消瘤方模拟剂口服,观察组患者给予扶正消瘤方口服,连续服药并随访12个月。比较两组患者肝功能指标、免疫学指标、血清肿瘤标志物、血清炎症相关因子、HBV再激活率、1年复发率情况。结果:经干预12个月,观察组患者的肝功能指标改善更明显,GGT、TBil、ALT、AST等水平显著低于对照组(P<0.05); 免疫学指标T淋巴细胞CD4+、CD4+/ CD8+、NK细胞水平明显高于对照组(P<0.05),CD8+水平、血清中CA242、CA724、AFP等肿瘤标志物含量、sB7-H3、IL-1β、TNF-α、PCT等炎症相关因子水平与对照组相比明显降低(P<0.05); 对照组中有7例血清HBV-DNA转为阳性(P<0.05); 观察组患者1年复发率7.69%,显著低于对照组患者的14.74%(P<0.05)。结论:扶正消瘤方更利于促进Ⅰ期乙肝相关肝癌TACE加RFA术后(正虚瘀结证)患者肝功能的恢复,提高机体免疫功能,降低血清肿瘤标志物水平,降低术后炎症反应程度,防止乙肝病毒再激活,降低复发风险。
Abstract:
Objective:To observe the therapeutic effect of Fuzheng Xiaoliu granule formula on stage Ⅰ hepatitis b related liver cancer patients after transcatheter arterial chemoembolization(TACE)+radiofrequency ablation(RFA)operation.Methods:312 patients were divided into the control group and the treatment group,156 patients respectively.Patients in the control group were given Fuzheng Xiaoliu granule simulation agent,and patients in the observation group were given Fuzheng Xiaoliu granule for 12 weeks.The short-term postoperative efficacy,liver function related indicators,immunological indicators,serum tumor markers,and inflammation-related indicators of patients in the two groups were observed and compared.Patients' postoperative HBV reactivation and recurrence rate were followed up.Results:After 12 weeks of postoperative treatment,the liver function of the observation group was significantly improved,with GGT,TBil,ALT,AST and other levels significantly lower than that of the control group(P<0.05).The levels of CD4+,CD4+/ CD8+ and NK cells in the observation group were significantly higher than those in the control group(P<0.05),while CD8+ levels were significantly lower than those in the control group(P<0.05).Serum tumor markers levels of CA242,CA724,AFP and serum inflammation-related indicators levels of sB7-H3,IL-1β,TNF-α and PCT in the observation group were significantly lower than those in the control group(P<0.05).7 patients in the control group turned positive for HBV-DNA(P<0.05).The recurrence rate in the observation group was 7.69%,which was significantly lower than 14.74% in the control group(P<0.05).Conclusion:Prescription of Fuzheng Xiaoliu granule is more conducive to promoting the recovery of liver function in patients with stage I hepatitis b related liver cancer after TACE+RFA operation,improving the immune function of the body,reducing the level of serum tumor markers,reducing the degree of postoperative inflammatory response,preventing the reactivation of hepatitis b virus,and reducing the risk of recurrence.

参考文献/References:

[1] 曹绍华,王庆庆,张金冉.索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响[J].陕西医学杂志,2020,49(5):615-618.
[2] Zeng Y,Mao Y,Shi Z,et al.Observation of therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on HBV-related liver cancer[J].Journal of BUON,2019,24(4):1414-1419.
[3] Hatanaka T,Arai H,Kakizaki S.Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma [J].World J Hepatol,2018,10(7):485-495.
[4] 顾 欢,白长川,刘 柳,等.中医药调控自噬治疗肝癌的研究现状[J].临床肝胆病杂志,2019,35(11):2582-2587.
[5] 国家卫生和计划生育委员会办公厅.原发性肝癌诊疗规范(2019年版)[J].肝癌电子杂志,2020,7(1):5-23.
[6] 王贵强,段钟平,王福生,等.慢性乙型肝炎防治指南(2019年版)[J].实用肝脏病杂志,2020,23(1):9-32.
[7] 张 强,李恒平.TACE术联合RFA术对高危部位原发性肝癌的临床疗效分析[J].中华普外科手术学杂志:电子版,2020,14(2):201-204.
[8] 蒋力平,刘兵元,张立鹏.乙肝相关肝癌患者行TACE+RFA术后HBV再激活的临床研究[J].介入放射学杂志,2018,27(2):171-174.
[9] Han T,Yang X,Zhang Y,et al.The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:a meta-analysis[J].Bioscience Trends,2019,13(5):374-381.
[10] 陈欣菊.早中期肝癌治疗“衷中补西”之临证感悟[J].中西医结合肝病杂志,2019,29(3):273-275.
[11] 李 毅,席素雅,石庆芳,等.黄芪注射液联合西药对单耐药肺结核患者抗炎、促炎因子及免疫调节作用研究[J].辽宁中医药大学学报,2019,21(8):149-152.
[12] 鲁 遇,余英才,梁永红.三脉菝葜醇提物及其不同极性萃取部位的抗肿瘤作用研究[J].中国药房,2019,30(19):2645-2649.
[13] 崔 宏,高琴琴,王效谦,等.白花蛇舌草注射剂调节Bcl-2/CytC信号通路诱导线粒体凋亡抑制肝癌细胞增殖的研究[J].陕西中医,2019,40(4):418-420.
[14] 张 晔,吕金朋,孙佳明,等.鳖甲抗肝纤维化研究进展[J].吉林中医药,2018,38(6):673-675.
[15] 张洪海,孙 玉,生守鹏,等.乙肝相关肝癌射频消融术后复发因素分析[J].北京医学,2019,41(6):468-471.
[16] 袁庆明.不同麻醉方法对肝癌切除术后患者肿瘤坏死因子-α、C反应蛋白以及T淋巴细胞亚群的影响[J].中华保健医学杂志,2017,19(6):509-512.
[17] 戴 锋,付守忠,王 斌,等.血清内sB7-H3与IL-1对乙肝相关肝癌患者的临床意义[J].海南医学院学报,2019,25(19):1496-1500.

相似文献/References:

[1]闫芍药,聂会勇,王锁良△.加味双柏散外敷联合耳穴压豆对肝癌介入治疗患者疼痛评分及生活质量影响*[J].陕西中医,2020,(12):1763.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.021]
　YAN Shaoyao,NIE Huiyong,WANG Suoliang..Effects of external application of Jiawei Shuangbai powder auricular acupoint combined with pressing with beans on pain score and quality of life in patients with liver cancer pain undergoing interventional therapy[J].,2020,(11):1763.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.021]
[2]梁瀞云,唐 燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,(11):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
　LIANG Jingyun,TANG Yan,SIMA ling,et al.Application of Chihu Shugan powder in liver diseases[J].,2022,(11):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]

备注/Memo

备注/Memo:
*国家科技重大专项(2018ZX10303502)
更新日期/Last Update: 2020-11-09